Introduction
Ribonucleotide reductase (RNR) is an essential enzyme for cell division as well as tumor growth (Finch et al., 1999) , which not only catalyzes the conserved reduction of ribonucleotides to deoxyribonucleotides, but also regulates the total rate of DNA synthesis to maintain a constant ratio of DNA to cell mass during cell proliferation and DNA repair (Jordan and Reichard, 1998; Shao et al., 2006; Xu et al., 2008) . There are two RNR isoforms in human (two dimers of M1-M2 subunits, or two dimers of M1-M2b subunits), and the catalytic function of the enzyme relies on the essential iron-tyrosyl radical center in M2 or M2b subunits (Jordan and Reichard, 1998) . Hence, it is a prime target for the development of chemotherapeutic agents.
Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone, or 3-AP; Fig. 1A ) is a metal-ion chelator and an experimental anticancer agent, which can disrupt the catalytic iron-tyrosyl radical center in M2 or M2b subunit of RNR via the formation of triapine-Fe(III) complex (Kowol et al., 2009) . Compared with hydroxyurea (HU), the only RNR-inhibitor drug currently used in chemotherapy, triapine is 1000-fold more potent for inhibition of RNR activity (Finch et al., 1999) . Studies have shown that triapine has a broaderspectrum antitumor activity and can significantly decrease RNR activity in a variety of cancer cell lines including leukemia, nonsmallcell lung cancer, renal cancer and melanoma, and enhances radiation-mediated cytotoxicity in cervical and colon cancers (Alvero et al., 2006; Finch et al., 1999 Finch et al., , 2000 Giles et al., 2003; Kuo et al., 2003; Li et al., 2001) . These promising pre-clinical studies have prompted a large number of clinical trials. To date, there have been 36 clinical trials of triapine worldwide for various cancers at various stages of studies (http://www.clinicaltrials.gov/ct2/results? term=triapine&Search=Search, accessed 14 December 2014). At the Case Comprehensive Cancer Center, the triapine studies have been focused on the investigation of sensitizing potential of triapine on radiation therapy of cervical and vaginal cancers (Kunos et al., 2009 (Kunos et al., , 2010a (Kunos et al., , 2010b (Kunos et al., , 2013 .
Despite the therapeutic significance of triapine, there is no validated analytical method published for quantitation of triapine in human biological samples. Several LC-UV assays have been described for the measurement of triapine in clinical studies (Mortazavi et al., 2013; Murren et al., 2003; Yee et al., 2006) ; however, when adopted, they often produced irreproducible results and were hindered by poor selectivity and inadequate limits of quantitation. Our recent study revealed that factors including solution pH, metal ions, other competing chelators and buffer composition can affect the reproducibility of an LC-UV method by influencing triapine complexation reaction, and the optimization of these factors is critical in the chromatography method development (Feng et al., 2014) .
In this work, we have developed and validated a reliable and selective LC-MS/MS method based on our recent findings (Feng et al., 2014) with adequate lower limit of quantitation (LLOQ) for determination of triapine in human plasma samples. Plasma samples were prepared by direct protein precipitation with acetonitrile. The method developed has been applied to the measurement of triapine in patient samples obtained from a phase I clinical trial.
Experimental Chemicals and materials
Triapine was provided by Vion Pharmaceuticals (New Haven, CT, USA) and used as the chemical standard for this work. 2 [(3 Fluoro 2 pyridinyl)methylene] hydrazinecarbothioamide (NSC 266749 or CAS 31181 41 6) was obtained from the Developmental Therapeutics Pro gram of the National Cancer Institute at the National Institutes of Health (Bethesda, MD, USA) and used as the internal standard (IS). HPLC grade methanol, ethylenediaminetetraacetic acid disodium salt (EDTA), and ammonium hydroxide were purchased from Sigma Aldrich (St Louis, MO, USA). Ammonium bicarbonate was from EMD Chemicals (Darmstadt, Germany). Deionized water was obtained from a Barnstead Model 7148 Nanopure® ultrapure water system (Thermo Scientific, Asheville, NC, USA). Six lots of human blank plasma (EDTA treated), six lots of human blank sera, and pooled human blank plasma were pur chased from Innovative Research (Novi, MI, USA).
Preparation of stock and standard solutions
The stock solutions of triapine (1.00 mg/mL) and NSC 266749 (1.00 mg/mL) were prepared individually by dissolving appropriate amount of each chemical in a known volume of methanol, and were kept at À20°C before use. The dilution solution which was prepared for dilution of the stock solutions to working standard solutions contained 25.0% acetonitrile and 75.0% ammonium bicarbonate EDTA (10.0 mM NH 4 HCO 3 and 1.00 mM EDTA, pH 8.50) buffer (v/v). The working solutions of triapine (1.00 μg/mL) and NSC 266749 (1.00 μg/mL) were freshly prepared by serial dilution of each stock solution with the dilution solution.
Triapine standard solutions (5. 00, 10.0, 15.0, 20.0, 50.0, 100, 150, 200 , 500, 800 and 1.00 × 10 3 ng/mL) and NSC 266749 internal stan dard solution (100 ng/mL) were prepared individually by serial dilution of the working solutions of triapine (1.00 μg/mL) and NSC 266749 (1.00 μg/mL) with the dilution solution. These standard solutions were used for the preparation of triapine plasma calibrators and quality controls (QCs).
Preparation of triapine plasma calibrators, QCs and patients' samples
Triapine plasma calibrators (0.250, 0.500, 1.00, 2.50, 5.00, 10.0, 25.0 and 50.0 ng/mL) and plasma quality controls (i.e. low , medium , high and dilution QCs 0.750, 7.50, 40.0 and 400 ng/mL) were prepared individu ally by mixing 200 μL of pooled blank human plasma and 10.0 μL of the corresponding triapine standard solution, which was 20 times the cali brator concentration. Patient plasma samples were prepared by mixing 200 μL of each patient's plasma with 10.0 μL of the dilution solution to match the sample matrix with those of the plasma calibrators and QCs. Single blank plasma (or triapine plasma zero calibrator) was prepared by mixing 200 μL of pooled blank human plasma with 10.0 μL of the di lution solution. Double blank plasma (containing neither triapine nor the IS) was prepared by mixing 200 μL of pooled blank human plasma with 20.0 μL of the dilution solution.
Prior to sample deproteinization, 10.0 μL of the IS solution (100 ng/mL) was added to each of the above plasma samples (e.g. calibrators includ ing zero calibrator, QCs and patient samples) except double blank plasma and mixed well.
Deproteinization of plasma samples
Each plasma sample was mixed with 880 μL of acetonitrile (at a ratio of 4 to 1) and vortexed for 30 s. Following by centrifugation at 15,000 × g for 10 min, the supernatant was pipetted into a 1.5 mL microcentrifuge tube and dried in a TurboVap® LV evaporator (Caliper Life Sciences, Hopkinton, MA, USA) at 30°C under nitrogen gas. The resulting residue was reconstituted in 110 μL of the dilution solution for LC MS/MS analysis.
Instrumentation
The LC MS/MS instrumentation system used consisted of a Shimadzu SIL 20AC autosampler (Shimadzu, Columbia, MD, USA), a Shimadzu LC 20AD HPLC unit with a Waters Xbridge Shield RP 18 column (3.5 μm; 2.1 × 50 mm) and a mobile phase containing methanol and 10.0 mM ammonium bicarbonate (pH 8.50) at a ratio of 25:75 (v/v) and an AB Sciex API 3200 turbo ionspray® triple quadrupole tandem mass spectrometer (AB Sciex, Foster City, CA, USA). The system was controlled by AB Sciex Analyst® (version 1.5.1) software.
The API 3200 tandem mass spectrometer was operated under the positive turbo ionspray ionization mode and was tuned by a mixture of 500 ng/mL tiapine and 500 ng/mL the IS in 50% methanol and 50% am monium bicarbonate (10.0 mM, pH 8.50) for both compound dependent and source dependent parameters. The multiple reaction monitoring (MRM) data were acquired with the following mass transitions: m/z 196 > 121 for triapine, and m/z 199 > 124 for the IS. The optimized instrument settings were as follows: curtain gas at 40; collision assisted dissociation gas at 8; ionization voltage at 4500 V; source temperature at 700; sheath gas at 50; desolvation gas at 40; desolvation potential at 40; entrance potential at 4; collision energy at 23; collision cell exit potential at 2; and resolution at unit.
The separation of triapine and the IS was accomplished by isocratic elution with the mobile phase at a flow rate of 0.300 mL/min. Prior to ini tial sample analysis, the column was equilibrated with the mobile phase at the flow rate for at least 30 min. During each run, 10.0 μL of reconstituted sample was injected into the system by the autosampler set at 4.0°C. The two position switch valve on the API 3200 tandem mass spectrometer was programmed to switch to the waste for the first 1.2 min and then switch to the mass spectrometer. Quantitation of triapine was carried out by the MRM mode of the tandem mass spec trometer, and the total instrument run time for each sample analysis was 4 min.
Method validation
The LC MS/MS method developed was validated in human plasma according to the US Food and Drug Administration (2001) 2007) in terms of selectivity, LLOQ, recovery, matrix effect, linear re sponse range, accuracy and precision, as well as stability for both short term sample processing and long term sample storage.
Selectivity and LLOQ
The selectivity of this method was evaluated by observing any interfernts at the same retention times and mass transitions of the analyte and the IS in six individual blank plasma and pooled blank plasma matrices, as well as in the pre dosed plasma from patients. The LLOQ of the method was defined as the lowest concentration of triapine plasma calibrator of the calibration curve with accuracy and precision ≤±20 and 20%, which was validated in six individual plasma, and pooled plasma matrices.
Matrix factor and recovery
The absolute matrix factor (MF) of triapine (or the IS) was determined by the mean peak area of triapine (or the IS) at a specified concentration in the deproteinized plasma matrix over that of triapine (or the IS) at the concentration in the mobile phase. The IS normalized MF was deter mined by the absolute MF of triapine over that of the IS. For this study, triapine QCs at two concentrations (0.750 and 40.0 ng/mL) with a fixed concentration of the IS (5.00 ng/mL) were prepared in six individual deproteinized plasma matrices and in the mobile phase.
The absolute recovery of triapine (or the IS) was determined by the mean peak area of triapine (or the IS) at a specific concentration in plasma matrix over the mean peak area of triapine (or the IS) at the con centration in the deproteinized plasma matrix multiplied by 100%. The IS normalized recovery was determined by the absolute recovery of triapine over that of the IS multiplying by 100%. For this study, triapine QCs at three concentrations (0.750, 7.50 and 40.0 ng/mL) with a fixed concentration of the IS (5.00 ng/mL) were prepared in the pooled human plasma and the deproteinized pooled human plasma.
Calibration curve
The triapine calibration curve in human plasma was established using double blank (plasma matrix with neither triapine nor the IS), single blank (plasma matrix with only the IS) and eight nonzero plasma calibra tors at the concentrations 0.250, 0.500, 1.00, 2.50, 5.00, 10.0, 25.0 and 50.0 ng/mL with the IS at the concentration 5.00 ng/mL. The peak area ratios of triapine to the IS (y) were plotted against triapine calibrator con centrations (x) with 1/x weighting.
Accuracy, precision and dilution study
Accuracy was expressed as percentage relative error (RE) and precision as the coefficient of variation (CV). In this work, the inter assay preci sion and accuracy were assessed by five parallel analyses of five iden tical QC samples at each of four QC concentrations (0.750, 7.50, 40.0 and 400 ng/mL). The intra assay precision and accuracy were assessed by five replicate analyses of each QC samples. The above studies also included the dilution study where the dilution QCs (400 ng/mL) were prepared and analyzed after 10 fold dilution by the pooled human blank plasma.
Stability study
The stability of triapine was investigated using stock and working solu tions (1.00 mg/mL and 1.00 μg/mL) and plasma low and high QCs (0.750 and 40.0 ng/mL), and the stability of NSC 266749 was also deter mined separately using NSC 266749 standard solution (100 ng/mL) and plasma sample containing 5.00 ng/mL of NSC 266749. In the NSC 266749 stability studies, triapine was used as the IS.
Stabilities of triapine stock and working solutions, triapine plasma QCs, NSC 266749 standard solution and plasma samples were assessed during short term (6 and 24 h) storage, standing on the bench top at 23°C and in the autosampler at 4°C (post preparative); during three freeze thaw cycles (where the samples were frozen at À20°C for at least 24 h and thawed at room temperature, 23°C, unassisted); and during long term storage (30 days) at À20°C. The stabilities of triapine and NSC 266749 were determined by comparing the mean peak area ratios of analyte to IS in the test sample with those of freshly prepared samples, and expressed as percentages. For this study, all experiments were done in five replicates.
Method application
The LC MS/MS method developed was tested for the measurement of triapine in patient plasma samples collected from a previous phase I Figure 2 . The mass spectra of triapine and the IS. The experimental conditions were described in the 'Instrumentation' section under the 'Experimental'. to preserve triapine from complexation. In this work, a dilution solution containing 25.0% acetonitrile and 75.0% ammonium bicarbonate-EDTA buffer (10.0 mM NH 4 HCO 3 and 1.00 mM EDTA, pH 8.50) was used for preparation of triapine working solution from its stock in methanol, as well as triapine standards from the working solution. It is also worth noting that triapine working and standard solutions prepared in Ultrapure HPLC-grade bottled water from Fisher Scientific (Fair Lawn, NJ, USA) could also give reproducible analytical signal if it was not contaminated by metal ions.
Plasma samples vs serum samples
Because EDTA can preserve triapine from complexation with metal ions, a comparison study was conducted on the absolute recovery and matrix effect of triapine from EDTA-treated human plasma and serum samples using two types of preparation methods, protein precipitation and liquid-liquid extraction. In this work, triapine plasma and serum samples (at 7.50 ng/mL) were prepared by spiking triapine standard solution in six lots of human blank plasma and six lots of human blank serum. These samples were prepared by protein precipitation with acetonitrile and methanol, as well as liquid-liquid extraction with acetyl acetate. As shown in Fig. 4 , the absolute recoveries of triapine were consistently higher from EDTA-treated plasma matrices (67-91%) than those from serum matrices (24-69%) by both types of sample preparation methods, and the absolute matrix factors were much closer to unity for plasma samples (0.750-0.800) than those of serum samples (0.120-0.200). Furthermore, protein precipitation with 4 volumes of acetonitrile produced greater recovery for triapine and comparable matrix factor among the sample preparation methods. Therefore, EDTA-treated plasma samples and protein precipitation by acetonitrile were used for the method development and sample preparation in the subsequent work. For clinical study of triapine, EDTA-treated tubes are highly recommended for blood collection.
Selectivity and LLOQ
The LC-MS/MS method developed was highly selective. As illustrated in Fig. 3(A) , there were no detectable interferents observed at the retention times and mass transitions of triapine and the IS from six individual plasma and the pooled plasma matrices, as well as the pre-dosed plasma from patients in a phase I clinical trial (Kunos et al., 2010a (Kunos et al., , 2010b .
The LLOQ of the method for quantitation of tripaine in human plasma was 0.250 ng/mL, which had signal-to-noise ratio of 23.5 Fig. 3B ). Table 1 summarized the accuracy and precision of the method at LLOQ. By five replicate measurements of each plasma matrix from six lots, the accuracy and precision were ≤±10 and ≤8%, respectively. These values were lower than those of the industry limits recommended by US Food and Drug Administration (≤±20 and ≤20%), which implied that the actual LLOQ of the method could be <0.250 ng/mL if it was validated when needed.
Matrix effect and recovery
Matrix effect was assessed by the MF using six independent lots of human plasmas. As shown in Table 2 , the absolute MFs of triapine and the IS were 0.57-0.78 and 0.64-0.80, respectively, and the IS normalized MFs were near unity (0.92-1.06). Hence, the matrix effect of human plasma on the analytical signals could be effectively corrected by the use of the IS.
The recovery data of triapine in pooled human plasma is shown in Table 3 . The absolute recoveries of triapine and the IS were 89-93 and 88-89%, respectively, and the IS normalized recovery was 101-104%. These results indicated that the protein precipitation procedure was sufficient to recover the analyte and the IS from human plasma.
Linearity
The linear regression equation obtained from six batches over 3 days was y = 0.373(±0.012)x À 0.00107(±0.00034) over the range 0.250-50.0 ng/mL with individual correlation coefficients >0.999. The accuracy and precision of individual plasma calibrators as summarized in Table 4 were ≤±6 and ≤8%, respectively.
Accuracy, precision and dilution integrity
As shown in Table 5 , the accuracy and precision were ≤±8 and ≤5% for the intra-assay study and ≤±7 and ≤4% for the interassay study, indicating the method developed was accurate and precise. In this study, dilution QC (400 ng/mL) was included because some of the patient plasma samples had triapine concentrations beyond the upper limit of quantitation (50.0 ng/mL) of the method. The accuracy and precision data of the dilution QC (≤±2 and ≤ 0.5% for the intra-assay study and ≤±7 and ≤ 1% for the inter-assay study) indicated that the integrity of plasma sample could be preserved after sample dilution. 
Stability
The stability study was conducted for triapine and the IS, and the results were summarized in Table 6 . At room temperature on the bench-top, tiapine and the IS stock solutions were stable for up to 24 h, whereas triapine and the IS in plasma were stable for at least 6 h. Triapine and the IS from plasma samples were stable in autosampler set at 4°C after sample preparation for 24 h. The recoveries of triapine and the IS after three freeze-thaw cycles were 96% for the low QC and 98% for the high QC, respectively, whereas the recovery of the IS was 92%. The studies also showed that there was no significant loss of triapine and the IS during long-term (30 days) storage at À20°C.
Application of the method
The feasibility of the LC-MS/MS method was demonstrated by the measurement of triapine concentrations in patient plasma samples collected from a previous phase I clinical trial of pelvic radiation, weekly cisplatin and triapine for locally advanced cervical cancer (Kunos et al., 2010a (Kunos et al., , 2010b . Figure 5 showed the triapine concentration-time profile in patients' blood samples on days 1 and 10 by 2 h triapine infusion at a dose of 25 mg/m 2 three times a week for 5 weeks. Compared with the HPLC-UV method used in the previous work (Kunos et al., 2010a (Kunos et al., , 2010b , the LC-MS/MS method developed not only could produce a comparable triapine concentration-time profile, but also was capable of measuring triapine concentrations (i.e. 0 h The measurement of triapine used NSC 266749 (5.00 ng/mL) as IS whereas the measurement of NSC 266749 used triapine (5.00 ng/mL) as IS. b The concentrations of stock solution and working solution were measured by serial dilution to 40.0 ng/mL with the dilution solution as described in the Experimental section. on day 10, and 24 h on days 1 and 10) otherwise below the LLOQ of the HPLC-UV method (20.0 ng/mL). Therefore, the LC-MS/MS method is better suited for the clinical study of triapine, and has an unparalleled selectivity and LLOQ compared with the HPLC-UV method.
Conclusion
This work has provided a detailed discussion on the development and validation of an LC-MS/MS method for the quantitation of triapine in human plasma. The method employs a simple deproteinization protocol for sample preparation, a reversed-phase chromatograph for analyte separation and a tandem mass spectrometer for analyte quantitation. EDTA is used as anticoagulant and metal-ion chelator to prevent the unwanted complexation reaction between triapine and metal-ion interferents. This method has a linear calibration range of 0.250-50.0 ng/mL with the accuracy and precision well suited for analysis of human plasma samples, filling the gap between the needs of clinical trials and the less sensitive HPLC-UV method. It is useful for clinical studies of triapine in human.
